Central venous catheter, CVC, centraal veneuze lijn, coagulopathy, coagulopathie, platelet count, thrombocytopenia, trombocytopenie
Conditions
Interventions
Eligible patients will be randomly assigned to either receiving one unit of platelet concentrate, or no platelet concentrate. There will be no placebo treatment. Rescue platelet concentrate will be av
Sponsors
Acamedic Medical Center
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age>18 years 2. Need for CVC placement at the clinician’s discretion 3. Platelet count between 10–50x109/L 4. INR<3.0 5. Informed consent
Exclusion criteria
Exclusion criteria: 1. Use of therapeutic anticoagulant therapy, except single antiplatelet therapy 2. Contra-indication for PC transfusion, such as Thrombotic thrombocytopenic purpura, or Congenital IgA deficiency 3. Randomization in the previous 24 hours 4. Patients with a history of congenital or acquired coagulation factor deficiency or bleeding diathesis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A procedure-related relevant bleeding, occurring within 24 hours after the procedure. A WHO grade 2-4 (appendix I) up to 24 hours of randomization is defined as relevant bleeding. Secondary study parameters/endpoints (if applicable) | — |
Secondary
| Measure | Time frame |
|---|---|
| - WHO grade 1 bleeding within 24 hours of CVC placement (appendix I) - Adjusted WHO bleeding score, HEME-bleeding score (appendices II and III) - Allergic transfusion reaction within 24 hours - Onset of acute lung injury within 48 hours. - Length of hospital stay - Number of RBCs and PC transfusions within 24 hours - Costs Hemoglobin and platelet count will be measured prior to the procedure and one hour and at 24 hours after the procedure and when clinically indicated. This is according to standard care. | — |
Contacts
Public ContactA.P.J. Vlaar
Department of Intensive Care Medicine Meibergdreef 9
Outcome results
None listed